Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksERGO.L Regulatory News (ERGO)

  • There is currently no data for ERGO

Block Listing Six Monthly Return

2 Jan 2019 07:00

RNS Number : 7694L
Ergomed plc
02 January 2019
 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 2 January 2019

 

Name of applicant:

Ergomed plc

Name of scheme:

Ergomed plc Long Term Incentive Plan

Period of return:

From:

2 July 2018

To:

31 December 2018

Balance of unallotted securities under scheme(s) from previous return:

1,800,000 (original admission)

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

nil

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

55,000

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1,745,000

Number and class of securities originally admitted and the date of admission

1,800,000 ordinary shares of 1p each - 2 July 2018

Total number of securities in issue at the end of the period

45,016,438 ordinary shares of 1p each

 

Name of contact:

Nick Blech - Deputy CFO

Telephone number of contact:

+44 (0)7768 547372

 

 Enquiries:

Ergomed plc

Tel: +44 (0) 1483 503205

Stephen Stamp (Chief Executive Officer)

Stuart Jackson (Chief Financial Officer)

 

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Broker)

 

Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Matthew Neal / Olivia Manser

 

ergomed@consilium-comms.com

MC-Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRFEWFWAFASEEE
Date   Source Headline
2nd Apr 20207:00 amRNSUpdate on Siltuximab Clinical Study
1st Apr 20207:00 amRNSTotal Voting Rights
30th Mar 20204:36 pmRNSHolding(s) in Company
30th Mar 20207:00 amRNSErgomed’s PrimeVigilance Supports COVID-19 Trial
25th Mar 20204:42 pmRNSSecond Price Monitoring Extn
25th Mar 20204:37 pmRNSPrice Monitoring Extension
25th Mar 202012:44 pmEQSEdison Investment Research Limited: Edison issues initiation on Ergomed (ERGO)
25th Mar 20207:00 amRNSAudited full year results
18th Mar 20208:39 amRNSErgomed Announces COVID-19 Clinical Study
4th Mar 20207:00 amRNSNotice of Preliminary Results
2nd Mar 20207:00 amRNSTotal Voting Rights
18th Feb 20203:19 pmRNSHoldings in Company
14th Feb 20207:00 amRNSDirector/PDMR Shareholding
7th Feb 20207:00 amRNSExercise of Share Options and Total Voting Rights
3rd Feb 20205:45 pmRNSHoldings in Company
30th Jan 20207:00 amRNSAward of Share Options
30th Jan 20207:00 amRNSExercise of Share Options and Total Voting Rights
29th Jan 20207:00 amRNS2019 Trading Update
20th Jan 20204:13 pmRNSHolding(s) in Company
20th Jan 20207:00 amRNSCOO, Lewis Cameron, joins Ergomed
17th Jan 20207:00 amRNSExercise of Options
13th Jan 20207:00 amRNSAcquisition of Ashfield Pharmacovigilance Inc.
2nd Jan 20207:00 amRNSTotal Voting Rights & Block Listing Return
19th Dec 201911:59 amRNSBlock Listing Application
2nd Dec 20197:00 amRNSAppointment of Chief Operating Officer
2nd Dec 20197:00 amRNSTotal Voting Rights
19th Nov 201910:30 amRNSHolding(s) in Company
14th Nov 20195:24 pmRNSHolding(s) in Company
8th Nov 20193:43 pmRNSHolding(s) in Company
8th Nov 20193:41 pmRNSHolding(s) in Company
7th Nov 20197:00 amRNSDirector's Dealing
1st Nov 20194:41 pmRNSSecond Price Monitoring Extn
1st Nov 20194:35 pmRNSPrice Monitoring Extension
1st Nov 20197:00 amRNSTotal Voting Rights
1st Oct 20197:00 amRNSTotal Voting Rights
25th Sep 20197:00 amRNSBoard Change
25th Sep 20197:00 amRNSInterim Results
18th Sep 20197:00 amRNSBoard Change
2nd Sep 20197:00 amRNSTotal Voting Rights
29th Aug 20197:00 amRNSNotice of Interim Results
20th Aug 20197:00 amRNSBoard Appointment
1st Aug 20197:00 amRNSTotal Voting Rights
26th Jul 20193:30 pmRNSHolding(s) in Company
24th Jul 20198:04 amRNSDirector/PDMR Shareholding
23rd Jul 20193:19 pmRNSHolding(s) in Company
22nd Jul 20197:00 amRNSBoard Appointments
22nd Jul 20197:00 amRNSErgomed H1 2019 Trading Update
19th Jul 20197:05 amRNSHolding(s) in Company
18th Jul 20197:00 amRNSHoldings in Company
10th Jul 20197:00 amRNSBoard Appointment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.